34 results
8-K
EX-99.2
NTRA
Natera, Inc.
9 May 24
Natera Reports First Quarter 2024 Financial Results
4:13pm
Value During Long - Term Follow - Up in Patients With Breast Cancer. JCO Precis Oncol. 2024;8:e2300456. Expanding data leadership in women’s cancers
8-K
EX-99.2
NTRA
Natera, Inc.
28 Feb 24
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
4:11pm
Not for reproduction or further distribution. 17 Extending data leadership in CRC BESPOKE - CRC ALTAIR INTERCEPT Patient reported outcomes MDACC prospective study … SG&A $ 630 – $ 650 Targeted investments in sales channels to capitalize on leadership position R&D $3 25 – $3 45 Stable v. 2023: continued focused
8-K
EX-99.2
NTRA
Natera, Inc.
9 Jan 24
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
7:07am
prepaid in exchange for discounts. On track for a cash flow breakeven quarter in 2024. 3
Not for reproduction or further distribution. 8 Market leadership
8-K
EX-99.1
i05ki0c xz
3 Aug 23
Natera Reports Second Quarter 2023 Financial Results
4:10pm
8-K
EX-99.2
tcru2k1 89
3 Aug 23
Natera Reports Second Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
zkzkhmhp
9 May 23
Natera Reports First Quarter 2023 Financial Results
4:01pm
8-K
EX-99.2
0cz1n he2m
9 May 23
Natera Reports First Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
i4uojz
8 Nov 22
Natera Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.2
paamvlpc04kzcnmr
8 Nov 22
Natera Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.2
ixn9v xgjvbl5f2aeq
4 Aug 22
Natera Reports Second Quarter 2022 Financial Results
4:13pm
8-K
EX-99.2
0v6o bwllb
5 May 22
Natera Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
c0vjnazuxp2ghg0
14 Mar 22
Departure of Directors or Certain Officers
7:30am
8-K
EX-99.2
3zxhvwns
24 Feb 22
Natera Reports Fourth Quarter and Full Year 2021 Financial Results
4:09pm
CORRESP
7tviv901owv5r2u
12 Nov 21
Correspondence with SEC
12:00am
UPLOAD
9cvedy sgicd
22 Sep 21
Letter from SEC
12:00am